case_images: PMC8235958_01
case_images: Abdominal MRI scans for Patient 1 (a-c), Patient 2 (d-f), and Patient 3 (g-i). MRI scans for Patient 1: (a) at diagnosis, (b) following induction therapy with eight cycles of COJEC, a cycle of adjuvant dinutuximab beta, and two cycles of adjuvant TVD, and (c) at the end of maintenance therapy with dinutuximab beta. MRI scans for Patient 2: (d) at diagnosis, (e) following induction therapy with eight cycles of COJEC, and (f) following three cycles of dinutuximab beta maintenance therapy. MRI scans for Patient 3: (g) at diagnosis, (h) following induction therapy with seven cycles of COJEC, and (i) following three cycles of second-line immunochemotherapy with irinotecan/temozolomide and dinutuximab beta and surgery of the primary abdominal tumor.
case_images: CRIPE2021-6610955.001.jpg
case_images: PMC8235958_03_CRIPE2021-6610955.001.jpg
case_images: fig1
case_images: The primary tumor was located in the left adrenal gland, with bone metastasis in the right side of the mandibula and local cervical lymphadenitis (Figure 1G). MRI scans following COJEC showed a reduction in the size of the primary tumor on the left adrenal gland and the metastasis on the mandibula, with full regression in the cervical lymph nodes (Figure 1H). Following cycle 3 of second-line immunochemotherapy, renal function was normal, as were bone marrow and MRI results (Figure 1I).
case_images: PMC8235958_02
case_images: Abdominal MRI scans for Patient 1 (a-c), Patient 2 (d-f), and Patient 3 (g-i). MRI scans for Patient 1: (a) at diagnosis, (b) following induction therapy with eight cycles of COJEC, a cycle of adjuvant dinutuximab beta, and two cycles of adjuvant TVD, and (c) at the end of maintenance therapy with dinutuximab beta. MRI scans for Patient 2: (d) at diagnosis, (e) following induction therapy with eight cycles of COJEC, and (f) following three cycles of dinutuximab beta maintenance therapy. MRI scans for Patient 3: (g) at diagnosis, (h) following induction therapy with seven cycles of COJEC, and (i) following three cycles of second-line immunochemotherapy with irinotecan/temozolomide and dinutuximab beta and surgery of the primary abdominal tumor.
case_images: CRIPE2021-6610955.001.jpg
case_images: PMC8235958_03_CRIPE2021-6610955.001.jpg
case_images: fig1
case_images: The primary tumor was located in the left adrenal gland, with bone metastasis in the right side of the mandibula and local cervical lymphadenitis (Figure 1G). MRI scans following COJEC showed a reduction in the size of the primary tumor on the left adrenal gland and the metastasis on the mandibula, with full regression in the cervical lymph nodes (Figure 1H). Following cycle 3 of second-line immunochemotherapy, renal function was normal, as were bone marrow and MRI results (Figure 1I).
case_images: PMC8235958_03
case_images: Abdominal MRI scans for Patient 1 (a-c), Patient 2 (d-f), and Patient 3 (g-i). MRI scans for Patient 1: (a) at diagnosis, (b) following induction therapy with eight cycles of COJEC, a cycle of adjuvant dinutuximab beta, and two cycles of adjuvant TVD, and (c) at the end of maintenance therapy with dinutuximab beta. MRI scans for Patient 2: (d) at diagnosis, (e) following induction therapy with eight cycles of COJEC, and (f) following three cycles of dinutuximab beta maintenance therapy. MRI scans for Patient 3: (g) at diagnosis, (h) following induction therapy with seven cycles of COJEC, and (i) following three cycles of second-line immunochemotherapy with irinotecan/temozolomide and dinutuximab beta and surgery of the primary abdominal tumor.
case_images: CRIPE2021-6610955.001.jpg
case_images: PMC8235958_03_CRIPE2021-6610955.001.jpg
case_images: fig1
case_images: The primary tumor was located in the left adrenal gland, with bone metastasis in the right side of the mandibula and local cervical lymphadenitis (Figure 1G). MRI scans following COJEC showed a reduction in the size of the primary tumor on the left adrenal gland and the metastasis on the mandibula, with full regression in the cervical lymph nodes (Figure 1H). Following cycle 3 of second-line immunochemotherapy, renal function was normal, as were bone marrow and MRI results (Figure 1I).